Sivik Global Healthcare LLC Acquires New Position in Madrigal Pharmaceuticals, Inc. $MDGL

Sivik Global Healthcare LLC bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 2,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,260,000.

Other institutional investors also recently bought and sold shares of the company. Persistent Asset Partners Ltd purchased a new position in shares of Madrigal Pharmaceuticals during the 2nd quarter worth $29,000. Global Retirement Partners LLC acquired a new stake in Madrigal Pharmaceuticals in the 2nd quarter worth about $34,000. GAMMA Investing LLC boosted its position in shares of Madrigal Pharmaceuticals by 35.4% in the second quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 45 shares during the last quarter. AlphaCentric Advisors LLC purchased a new position in Madrigal Pharmaceuticals during the first quarter worth approximately $93,000. Finally, Harbor Investment Advisory LLC increased its holdings in shares of Madrigal Pharmaceuticals by 1,385.7% during the 2nd quarter. Harbor Investment Advisory LLC now owns 208 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 194 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Madrigal Pharmaceuticals

In related news, CEO William Sibold sold 6,362 shares of Madrigal Pharmaceuticals stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total transaction of $3,407,423.58. Following the sale, the chief executive officer owned 202,967 shares of the company’s stock, valued at $108,707,095.53. The trade was a 3.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon T. Kelley sold 664 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $514.97, for a total transaction of $341,940.08. Following the completion of the transaction, the general counsel owned 11,474 shares in the company, valued at $5,908,765.78. This represents a 5.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 12,247 shares of company stock valued at $6,581,182 over the last 90 days. Insiders own 17.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Piper Sandler reiterated an “overweight” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, June 24th. HC Wainwright restated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 31st. The Goldman Sachs Group assumed coverage on Madrigal Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $704.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. Finally, Wolfe Research raised Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price objective on the stock in a research report on Tuesday, August 4th. Fifteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $710.20.

Madrigal Pharmaceuticals Stock Down 3.4%

NASDAQ MDGL traded down $15.90 on Tuesday, reaching $451.25. The company had a trading volume of 102,308 shares, compared to its average volume of 330,816. The firm has a market capitalization of $10.42 billion, a PE ratio of -35.01 and a beta of -1.04. Madrigal Pharmaceuticals, Inc. has a 1 year low of $393.61 and a 1 year high of $615.00. The firm has a 50-day moving average of $519.47 and a 200-day moving average of $518.32. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.68) by $0.69. The company had revenue of $364.25 million during the quarter, compared to the consensus estimate of $352.13 million. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. Madrigal Pharmaceuticals’s revenue for the quarter was up 71.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.90) earnings per share. On average, equities research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.03 EPS for the current fiscal year.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for chronic liver diseases. The company’s primary focus is metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease that can lead to significant liver fibrosis, cirrhosis and other complications.

Madrigal’s lead product, Rezdiffra (resmetirom), is an oral thyroid hormone receptor beta agonist. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH accompanied by moderate to advanced liver fibrosis.